Ginkgetin

Other Names

3''',8-Biflavone, 4',5,5'',7-tetrahydroxy-4''',7''-dimethoxy-4''',5,5'',7''-tetrahydroxy-4',7-dimethoxy-(3'->8'')-biflavone4''',7''-Dimethylamentoflavone4H-1-Benzopyran-4-one, 5,7-dihydroxy-8-[5-(5-hydroxy-7-methoxy-4-oxo-4H-1-benzopyran-2-yl)-2-methoxyphenyl]-2-(4-hydroxyphenyl)-5,7-Dihydroxy-8-[5-(5-hydroxy-7-methoxy-4-oxo-4H-1-benzopyran-2-yl)-2-methoxyphenyl]-2-(4-hydroxyphenyl)-4H-1-benzopyran-4-one5,7-Dihydroxy-8-[5-(5-hydroxy-7-methoxy-4-oxo-4H-chromen-2-yl)-2-methoxyphenyl]-2-(4-hydroxyphenyl)-4H-chromen-4-one7,4'-DimethylamentoflavoneAmentoflavone 4''',7''-dimethyl etherAmentoflavone 7'',4'''-dimethyl etherGinkgotin

Synopsis

Ginkgetin: A Comprehensive Reference

1. Identity, Chemistry, and Natural Sources

1.1 Chemical Identity

Ginkgetin is a flavonoid dimer — specifically, a 7,4′-dimethyl ether derivative of the apigenin dimer amentoflavone. It is the first isolated biflavonoid, obtained in the form of a yellow powder from the leaves of Ginkgo biloba, and the first biflavonoid whose structure was described. Its molecular formula is C₃₂H₂₂O₁₀. Structurally, ginkgetin belongs to the 3′-8″-linked biflavone subclass, which distinguishes it from other biflavonoids like amentoflavone (the parent compound of this subclass) and its monomeric counterparts such as apigenin.

This unique C-C linked dimeric architecture confers distinct molecular planarity and lipophilicity, contributing to its enhanced membrane permeability and multitarget engagement capabilities. It is a derivative of amentoflavone with two methoxy groups (7,4′-dimethylamentoflavone). More precisely, ginkgetin is designated as 7,4′-di-O-methylamentoflavone, meaning that two of amentoflavone's hydroxyl groups — at the 7 and 4′ positions — are methylated.

1.2 Primary Botanical Source and Related Plant Species

Ginkgo biloba L. (family Ginkgoaceae) is the most prominent source, and ginkgetin was first identified and isolated from its leaves. G. biloba is the most mystifying Chinese plant species existing from millennia and has been the focus of both scientists and the public. Commonly referred to as the maidenhair tree, the species stands out with its distinctive fan-shaped leaves and its extensive history as a therapeutic plant. Known for surviving over 200 million years, it is celebrated as one of the most ancient living tree species on Earth, and is native to China, often called a "living fossil" due to its continuous existence despite dramatic changes in climate and environment.

Ginkgetin is the first known biflavonoid, a flavonoid dimer isolated from Ginkgo biloba L. Its occurrence was later discovered in more than 20 different plant species, most of which are known for their use in traditional medicine. Although the distribution of biflavonoids in the plant kingdom is restricted to only a few plant families, they constitute a major class of polyphenolic compounds serving as important chemotaxonomic markers for various species.

1.3 Occurrence Within Ginkgo biloba

The most commonly reported biflavonoids in ginkgo are ginkgetin, isoginkgetin, amentoflavone, bilobetin, and sciadopitysin, while the presence of sesquojaflavone, podocarpusflavone A, and 5′-methoxybilobetin has also been reported. Quantitative profiling across a large population of trees reveals that ginkgetin ranks third in abundance among the five major biflavonoids, with a consistent hierarchical order of sciadopitysin > isoginkgetin > ginkgetin > bilobetin > amentoflavone; sciadopitysin emerged as the predominant constituent (1532.89 ± 544.13 µg/g dry weight).

The bioactive potential of G. biloba is associated with the presence of flavonoids and terpene trilactones, but many other compounds may also have synergistic effects. Flavonoid dimers — biflavonoids — are important constituents of ginkgo phytopharmaceuticals.

1.4 Common Forms and Preparations

As an isolated compound, ginkgetin is not a primary constituent of standard commercial ginkgo extracts. Ginkgetin exhibits relatively low oral bioavailability due to its biflavonoid structure and high lipophilicity, which result in poor aqueous solubility and limited intestinal absorption. In the context of available preparations:

Pure isolate (research grade): Ginkgetin is available as a research chemical, typically as a powder in milligram quantities for laboratory use, with purity commonly reported at ≥98%.
Standardized Ginkgo biloba leaf extracts (e.g., EGb 761®): These widely used extracts are standardized primarily for flavonol glycosides (24%) and terpene trilactones (6%), not for biflavone content. Ginkgetin is present only as a minor component in such preparations.
Enriched biflavone extracts: Some specialized extracts may standardize for biflavone content (ginkgetin, isoginkgetin, bilobetin), but this is not common in consumer products.
Ginkgo leaf powder: Raw or minimally processed ginkgo leaf powder contains ginkgetin as a trace constituent alongside other biflavonoids.

It is crucial to note that the promising pharmacological profile of ginkgetin is predominantly derived from preclinical studies, and clinical evidence in humans remains to be established. Despite these promising findings, the clinical translation of ginkgetin remains limited by challenges related to pharmacokinetics, bioavailability, and druggability.

2. Traditional and Historical Use

2.1 Ginkgo biloba in Traditional Chinese Medicine

The traditional use documented historically concerns the whole Ginkgo biloba plant and its extracts, not ginkgetin as an isolated compound, since the latter was not identified until modern times. Ginkgo biloba was first recorded as a medicinal plant in the Chinese Materia Medica Shen Nong Ben Cao Jing approximately 2,000 years ago, and only the seeds were reported to be used as medicine at that time. Its seeds have been used as snacks and medical materials in Traditional Chinese Medicine (TCM), while over the last century its leaf extracts emerged as a source of rising pharmaceutical commerce related to brain health in Western medicine.

The Ming Dynasty Compendium of Materia Medica and Qing Dynasty Bencao Fengyuan recorded that this herbal medicine can reduce phlegm, clear poison, treat diarrhea and frequent urination. Green ginkgo leaves have been used for brain disorders, circulatory disorders, and respiratory diseases as traditional Chinese medicine, while the fallen leaves have been used as insecticides and fertilizer. Ginkgo has been used as a heart medicine in Chinese phytomedicine since at least 1509. It has also been used traditionally for lung ailments, brain function, and inner ear disorders.

A 16th-century Chinese text, the Ben Cao Gang Mu by Li Shi-Zhen, contains an ancient prescription of ginkgo seeds for skin infections. The leaves and seeds of G. biloba have huge spiritual, horticultural, and medicinal significance.

2.2 Important Historical Distinction

It is important to note that ginkgetin as a specific chemical entity was identified and isolated only during the modern era of phytochemical research. For more than 30 years, ginkgetin has been the focus of scientific attention as a possible effective anticancer agent and as an agent with beneficial effects on neurological diseases. The traditional preparations — decoctions, leaf powders, seed preparations — delivered ginkgetin as a minor component within a complex mixture of bioactive compounds, and historical healers had no knowledge of or intent to isolate this specific biflavone. No traditional medical system has used or referenced ginkgetin specifically, only the parent plant material.

3. Key Constituents and Chemical Relationships

Within the context of Ginkgo biloba, ginkgetin belongs to the biflavonoid fraction, which is distinct from the two other principal bioactive fractions: the flavonol glycosides (quercetin, kaempferol, isorhamnetin glycosides) and the terpene lactones (ginkgolides A, B, C, J, and bilobalide). Currently, the presence of 13 biflavonoids has been reported in ginkgo, of which amentoflavone, bilobetin, sciadopitysin, ginkgetin, and isoginkgetin are the most common.

Amentoflavone is a dimer of two apigenins with six hydroxyl groups that can be easily replaced by a methoxyl group. Therefore, other biflavonoids can also be considered as derivatives of amentoflavone. Ginkgetin's co-occurring biflavones in ginkgo include:

Amentoflavone — the unmethylated parent biflavone
Bilobetin — a mono-methylated derivative (4′-O-methylamentoflavone)
Isoginkgetin — the 4′,4′′′-di-O-methyl isomer of ginkgetin
Sciadopitysin — the tri-methylated derivative

An array of biological properties has been extensively reported in literature for biflavonoids and biflavonoid-rich preparations from plants, such as anti-inflammatory, anti-bacterial, anti-oxidant, anti-cancer, platelet adhesion, and histamine release halting capability, suggesting their potential in treating different diseases.

4. Established and Proposed Mechanisms of Action

4.1 Inhibition of Phospholipase A₂ and the Eicosanoid Pathway

One of ginkgetin's most consistently described mechanisms is suppression of the arachidonic acid cascade. Ginkgetin, a biflavonoid from Ginkgo biloba leaves, was previously demonstrated to inhibit phospholipase A₂ and to suppress proinflammatory gene expression such as cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase. Several natural biflavonoids including ochnaflavone and ginkgetin inhibit phospholipase A₂. Most importantly, certain biflavonoids exhibit anti-inflammatory activity through the regulation of proinflammatory gene expression in vitro and in vivo.

Ginkgetin (1–10 µM) and the biflavonoid mixture (10–50 µg/ml), mainly a 1:1 mixture of ginkgetin and isoginkgetin, from G. biloba leaves, inhibited production of prostaglandin E₂ from lipopolysaccharide-induced RAW 264.7 cells. This inhibition was mediated, at least in part, by down-regulation of COX-2 expression, but not by direct inhibition of COX-1 or COX-2 activity. This distinction is pharmacologically relevant: ginkgetin does not act as a direct COX enzyme inhibitor in the manner of classical NSAIDs, but instead suppresses the upstream induction of COX-2 expression.

4.2 Phosphodiesterase-4 (PDE4) Inhibition

PDE4 plays a key role in the inflammatory process by converting cyclic AMP (cAMP) to AMP, and its inhibition can suppress the production of inflammatory cytokines. Research has identified ginkgetin as a natural PDE4 inhibitor; PDE4 inhibition leads to elevated intracellular cAMP levels, which in turn suppresses inflammatory cytokine production. This mechanism is shared by pharmaceutical PDE4 inhibitors used clinically for conditions such as COPD and psoriasis.

4.3 NF-κB and Pro-inflammatory Cytokine Suppression

Ginkgetin diminished the expression of inflammation-associated proteins such as inducible nitric oxide synthase (iNOS), intercellular adhesion molecule 1 (ICAM-1), cyclooxygenase-2, prostaglandin E₂, interleukins, and TNF-α in in vitro and in vivo studies. In the context of skin inflammation, the expression of the proinflammatory gene interleukin-1β was suppressed by ginkgetin.

4.4 Anticancer Mechanisms: Cell Cycle Arrest, Apoptosis, and Autophagy

Ginkgetin combats cancer progression by arresting cell cycle, inducing apoptosis, stimulating autophagy, and targeting many deregulated signaling pathways such as JAK/STAT and MAPKs.

In hepatocellular carcinoma cells (HepG2), ginkgetin treatment increased caspase-3 activity and cytochrome c release but not caspase-8 activity, implying that ginkgetin mediates cell apoptosis through the mitochondrial pathway.

In renal cell carcinoma (786-O) cells, ginkgetin induced apoptosis and increased the levels of caspase-8, caspase-9, and caspase-3, while treated cells also showed decreased levels of JAK2 and phosphorylated-STAT3 whether or not IL-6 was pretreated.

In breast cancer cells, ginkgetin treatment downregulated PFKFB3, cyclin D1, and survivin — targets of the estrogen receptor — while the anti-proliferative effects were sufficient to suppress the growth stimulated by estradiol. Ginkgetin did not significantly affect the viability of MDA-MB-231 cells, which are ER-negative cells.

In non-small cell lung cancer (NSCLC), ginkgetin demonstrated anticancer activity with strong autophagy induction, and a similar anticancer effect was seen as with the chemotherapeutic drug cisplatin without obvious toxicity in a nude mouse xenograft model. Ginkgetin was proposed as a potential compound for novel anticancer drug development for NSCLC.

4.5 Neuroprotective Mechanisms

Possible neuroprotective mechanisms of ginkgetin include inhibition of reactive oxygen species, inhibition of β-secretase, inhibition of Aβ fibril formation, amelioration of inflammation, and antimicrobial activity.

In Parkinson's disease models, ginkgetin exhibits neuroprotection against neuronal cell damage in the Parkinson's disease model by reducing intracellular reactive oxygen species (ROS), sustaining matrix metalloproteinase, suppressing tyrosine hydroxylase in the substantia nigra, and increasing superoxide dismutase activity in the striatum. A notable mechanism is its ability to chelate iron and regulate cerebral iron homeostasis, thereby alleviating iron-mediated toxicity.

In Alzheimer's disease models, ginkgetin exerted neuroprotective effects in the brain by decreasing plasma amyloid β and amyloid β plaque levels, inhibiting cerebral microhemorrhage, and reducing astrogliosis in APP/PS1 mice.

In cerebral ischemia/reperfusion models, ginkgetin exhibits neuroprotection against ischemia/reperfusion-induced rat injury by downregulating pro-inflammatory cytokines and blocking the TLR4/NF-κB pathway. Additionally, ginkgetin attenuated I/R-induced autophagy activation, pyramidal neuron death in cerebral I/R, and reduced I/R-induced upregulation of p53, suggesting that ginkgetin can attenuate cerebral ischemia/reperfusion-induced autophagy and apoptosis by inhibiting the NF-κB/p53 pathway.

4.6 Cardiovascular Mechanisms

For cardiovascular diseases, ginkgetin exhibited substantial vasodilation via inhibition of cyclic GMP-phosphodiesterase-5 and enhanced endothelial NOS expression. It also significantly diminished atherosclerosis in rat through increasing high-density lipoprotein while reducing low-density lipoprotein and triglyceride levels in blood serum, hence improved the lipid profile.

In a study using human platelet preparations, at low concentrations (0.5–1 µM), ginkgetin exhibited robust inhibition of collagen and arachidonic acid (AA)-induced platelet aggregation. Thrombin and U46619 remained impervious to ginkgetin's influence. Ginkgetin's modulatory effect extended to ATP release, P-selectin expression, intracellular calcium ([Ca²⁺]i) levels, and thromboxane A₂ formation. Ginkgetin exerts its inhibitory effects by targeting key signaling cascades, notably PLCγ2/PKC, PI3K-Akt-GSK3β, and MAPKs.

4.7 STING Pathway Inhibition and Anti-aging

One study found that ginkgetin, an active ingredient of Ginkgo biloba extract, can alleviate cellular senescence and improve pathologies in multiple tissues of aging mice. To reveal the molecular mechanism of its anti-aging effect, a graph convolutional network-based drug "on-target" pathway prediction algorithm was employed. The results indicated that the cGAS-STING pathway may be a potential target for ginkgetin. Subsequent cell biological and biophysical data confirmed that ginkgetin directly binds to the carboxy-terminal domain of STING protein, thereby inhibiting STING activation and signaling.

4.8 Antiviral Mechanisms

Early work established antiviral mechanisms at the level of viral transcription. Screening of plant extracts found that a biflavone from Cephalotaxus drupacea, identified as ginkgetin, is active against herpes simplex virus type 1 (HSV-1). This compound caused dose-dependent inhibition of virus replication with a 50% cytotoxic activity at 12.8 µg/ml and 50% anti-HSV-1 activity at 0.91 µg/ml, the therapeutic index being 14.1. Ginkgetin also showed inhibitory effects against HSV type 2 and human cytomegalovirus with therapeutic indices of 13.8 and 11.6, respectively. Both adsorption of HSV-1 to host cells and virus penetration into cells were unaffected by ginkgetin. Ginkgetin suppressed viral protein synthesis when added at various steps of HSV-1 replication and exerted strong inhibition of transcription of the immediate-early genes.

5. Scientific Evidence by Area of Use

5.1 Inflammation and Skin Disorders

Evidence type: Animal and cell-based preclinical studies. No human clinical trials for ginkgetin in isolation.

In a study examining effects on an animal model of chronic skin inflammation and proinflammatory gene expression, when topically applied to ICR mouse ear, ginkgetin (20–80 µg/ear/treatment) inhibited ear edema (22.8–30.5%) and prostaglandin E₂ production (30.2–31.1%) induced by multiple treatment with TPA for 7 consecutive days. By histological comparison, ginkgetin was also found to reduce epidermal hyperplasia.

At total doses of 1,000 µg/site on the dorsal skin (15 mm × 15 mm), ginkgetin inhibited prostaglandin E₂ production by 65.6% along with a marked suppression of COX-2 induction. In addition, ginkgetin and the biflavonoid mixture (100–1,000 µg/ear) dose-dependently inhibited skin inflammation of croton oil-induced ear edema in mice by topical application. The study suggests that ginkgetin from G. biloba leaves down-regulates COX-2 induction in vivo, and this down-regulating potential is associated with an anti-inflammatory activity against skin inflammatory responses.

In a rat adjuvant-induced arthritis model, ginkgetin was reported to be a phospholipase A₂ inhibitor and this compound showed potent antiarthritic activity in rat adjuvant-induced arthritis as well as analgesic activity.

Limitation: All inflammation and skin studies are in animal or cell models. No randomized controlled trials in human subjects for ginkgetin alone have been identified in the peer-reviewed literature.

5.2 Oncology / Anti-tumor Activity

Evidence type: Cell-based (in vitro) and xenograft animal models. No human clinical trials.

Ginkgetin displays several anticancer properties, including activity against leukemia, lung, colon, breast, kidney, prostate, cervical, and ovarian cancers, through cell cycle arrest, triggering apoptosis, inducing autophagy, and preventing angiogenesis.

Hepatocellular carcinoma (HCC): Cellular morphology observation revealed that ginkgetin induced typical apoptotic morphological features in HepG2 cells. Ginkgetin treatment increased caspase-3 activity and cytochrome c release but not caspase-8 activity, implying mitochondrial pathway apoptosis. The tumor formation experiment in nude mice showed that ginkgetin administration inhibited tumor growth. These results suggest that ginkgetin could be a cell apoptosis stimulator by affecting the balance between cell proliferation and apoptosis.

Ovarian cancer: Using OC cell lines A2780, SK-OV-3, and CP70 for in vitro experiments, ginkgetin inhibited the proliferation and induced apoptosis in OC cells, reduced migration and invasion, and in vivo study showed that ginkgetin significantly reduced tumor volume in the xenograft mouse model. The anti-tumor effects of ginkgetin were associated with a downregulation of p-STAT3, p-ERK, and SIRT1 both in vitro and in vivo, suggesting that ginkgetin exhibits anti-tumor activity in OC cells via inhibiting the JAK2/STAT3 and MAPK pathways and SIRT1 protein.

Renal cell carcinoma (RCC): Ginkgetin suppressed the growth of 786-O cells in dose- and time-dependent manners with IC₅₀ values of 7.23 µM. Ginkgetin induced apoptosis of 786-O cells and increased the levels of caspase-8, caspase-9, and caspase-3. The results indicate ginkgetin possesses obvious inhibitory effects on proliferation of 786-O, likely due to its inhibition of the JAK2/STAT3 pathway, and these findings imply ginkgetin is a potential therapeutic medicine for RCC.

Breast cancer: In previous studies, ginkgetin was cytotoxic against tumor cells with a half-maximal inhibitory concentration (IC₅₀) of approximately 10 µM. MCF-7 and T-47D human breast cancer cells exposed to 5 or 10 µM of ginkgetin demonstrated a decrease in cell number and increased indication of apoptosis. The MTT assay revealed that ginkgetin reduced cell viability by approximately 50% in both cell lines at a concentration of 10 µM.

Leukemia: Ginkgetin inhibited the proliferation of K562 cells in a dose- and time-dependent manner, with concentrations required to induce 50% death of K562 cells at 24, 48, and 72 hours being 38.9, 31.3, and 19.2 µM, respectively. Treatment with ginkgetin increased K562 apoptosis in vitro along with increased levels of TNF-α, and anti-TNF-α antibody prevented ginkgetin-induced K562 cell apoptosis and growth inhibition via deactivation of caspase-8, caspase-9, and caspase-3.

Lung cancer: Experiments confirmed that ginkgetin inhibits the Akt/GSK-3β/Snail and Wnt/β-catenin cascade initiation in A549, H1299, and LLC cells, preventing metastasis, and these results aligned with the hypotheses derived from network pharmacology analysis.

Cervical cancer: The results of qRT-PCR and ELISA showed that the levels of expression of TNF-α, IL-1β, and IL-8 mRNAs were significantly and dose-dependently reduced in HeLa cells after 48 hours of treatment with ginkgetin. The anti-proliferative effect of ginkgetin on HeLa cells is exerted via a mechanism involving the p38/NF-κB pathway.

Limitation: All anticancer data are from cell lines and animal xenograft models. There are no clinical trials of ginkgetin as an anticancer agent in humans. Extrapolation of in vitro concentrations to in vivo therapeutic relevance remains speculative given known bioavailability constraints.

5.3 Neuroprotection

Evidence type: Animal and cell models. No human clinical trials for isolated ginkgetin.

There is evidence of protection against neuronal damage caused by ischemic strokes, neurotumors, Alzheimer's disease (AD), and Parkinson's disease (PD) in preclinical studies. Beneficial effects in ischemic strokes have been demonstrated in animal studies in which injection of ginkgetin before or after onset of the stroke showed protection from neuronal damage.

Cerebral ischemia/reperfusion: Administration of ginkgetin (25, 50, and 100 mg/kg) significantly attenuated brain infarction volumes and neurologic deficits compared with the ischemia/reperfusion group in a middle cerebral artery occlusion/reperfusion rat model. Some researchers used oxygen glucose deprivation (OGD) cellular and MCAO animal models to study neuroprotective activity of ginkgetin and reported that ginkgetin treatment converted microglia from M1 type to M2 type and inhibited neuroinflammation.

Parkinson's disease: Ginkgetin's role in Parkinson's disease involves mitigating dopaminergic neuron loss; in MPTP-induced models, ginkgetin improves motor function, reduces oxidative stress, and inhibits apoptosis. A notable mechanism is its ability to chelate iron and regulate cerebral iron homeostasis, thereby alleviating iron-mediated toxicity.

Alzheimer's disease: AD protection has been the most studied to date. Possible mechanisms include inhibition of reactive oxygen species, inhibition of β-secretase, inhibition of Aβ fibril formation, amelioration of inflammation, and antimicrobial activity.

Limitation: All neuroprotective evidence is from animal studies (primarily rodent) and in vitro cell models. Ginkgetin's high lipophilicity, while potentially beneficial for blood-brain barrier (BBB) penetration, must be balanced against its poor aqueous solubility, and most in vitro neuroprotection studies have employed concentrations that may not reflect achievable brain tissue levels. No human trials exist.

5.4 Cardiovascular Health

Evidence type: Animal models and an in vitro study using human platelet preparations. Limited human data.

Ginkgetin has been reported to ameliorate experimental atherosclerosis in rats. Mechanistically, ginkgetin exhibited substantial vasodilation via inhibition of cyclic GMP-phosphodiesterase-5 and enhanced endothelial NOS expression.

One notable study directly used human platelet material. Ginkgetin from Ginkgo biloba L., renowned for its anticancer and neuroprotective properties, was investigated for its impact on platelet activation in human platelets. At low concentrations (0.5–1 µM), ginkgetin exhibited robust inhibition of collagen and arachidonic acid (AA)-induced platelet aggregation. Intriguingly, thrombin and U46619 remained impervious to ginkgetin's influence. This study involved isolated human platelets in a laboratory setting and does not constitute a clinical trial.

Limitation: The platelet aggregation study, while using human-derived material, was performed in a controlled laboratory environment (ex vivo), not in human subjects. Atherosclerosis data are from rat models only. No cardiovascular endpoint clinical trials involving isolated ginkgetin exist.

5.5 Antimicrobial Activity

Evidence type: In vitro assays only.

Emerging evidence highlights ginkgetin's antibacterial and antivirulence properties through the inhibition of biofilm formation and quorum sensing.

Antiviral activity against herpesviruses was established in early laboratory work: ginkgetin is active against herpes simplex virus type 1 (HSV-1), causing dose-dependent inhibition of virus replication with a 50% anti-HSV-1 activity at 0.91 µg/ml and a therapeutic index of 14.1. Ginkgetin also showed inhibitory effects against HSV type 2 and human cytomegalovirus with therapeutic indices of 13.8 and 11.6, respectively.

Limitation: All antimicrobial data are from cell-culture assays. No clinical antimicrobial trials have been conducted with isolated ginkgetin.

5.6 Senescence and Anti-aging

Evidence type: Cell models and in vivo mouse studies. No human data.

One study found that ginkgetin, an active ingredient of Ginkgo biloba extract, can alleviate cellular senescence and improve pathologies in multiple tissues of aging mice. Subsequent cell biological and biophysical data confirmed that ginkgetin directly binds to the carboxy-terminal domain of STING protein, thereby inhibiting STING activation and signaling. This study confirmed STING serves as a critical target for ginkgetin in alleviating inflammation and senescence, elucidating the specific component and molecular mechanism underlying the anti-aging effect of Ginkgo biloba extract and providing a theoretical basis for its therapeutic use.

6. Body Systems Associated with Ginkgetin Research

Based on the preclinical literature, ginkgetin has been investigated across the following body systems:

Central Nervous System: Neuroprotection in ischemia, Alzheimer's disease, Parkinson's disease, and neuro-oncology.
Cardiovascular System: Antiplatelet effects, vasodilation, anti-atherosclerosis, lipid modulation.
Immune and Inflammatory System: Inhibition of PDE4, COX-2, iNOS, NF-κB, and multiple pro-inflammatory cytokines; chronic skin inflammation.
Oncology (multiple organ systems): Liver, lung, breast, ovary, kidney, cervix, and hematopoietic cancers have been studied in laboratory models.
Musculoskeletal System: Anti-arthritic activity demonstrated in adjuvant-induced arthritis models.
Integumentary System: Topical anti-inflammatory activity in skin edema and epidermal hyperplasia models.
Antiviral / Antimicrobial: Activity against herpes viruses and potentially against bacterial biofilms.
Cellular Aging / Senescence: STING pathway modulation with effects on multi-tissue senescence markers.

7. Dosages Reported in Preclinical Studies

No established or approved human dosage exists for isolated ginkgetin. All dosage data in the literature are derived from cell culture or animal studies. The following figures are reported directly from peer-reviewed sources and are provided for scientific reference only.

7.1 In Vitro (Cell Studies)

Ginkgetin at 1–10 µM inhibited prostaglandin E₂ production from LPS-induced RAW 264.7 macrophage cells.
Ginkgetin suppressed growth of 786-O renal carcinoma cells with IC₅₀ values of 7.23 µM.
MCF-7 and T-47D breast cancer cells were exposed to 5 or 10 µM of ginkgetin, and ginkgetin reduced cell viability by approximately 50% in both cell lines at a concentration of 10 µM.
Concentrations of ginkgetin required to induce 50% death of K562 leukemia cells at 24, 48, and 72 hours were 38.9, 31.3, and 19.2 µM, respectively.
At low concentrations (0.5–1 µM), ginkgetin exhibited robust inhibition of collagen and arachidonic acid-induced platelet aggregation in human platelet preparations.
HepG2 hepatocellular carcinoma cells were incubated with 12.5, 25, and 50 µM ginkgetin for 48 hours in apoptosis studies.

7.2 Animal Studies

Administration of ginkgetin at doses of 25, 50, and 100 mg/kg significantly attenuated brain infarction volumes and neurologic deficits in a rat cerebral ischemia/reperfusion model.
Topical application of ginkgetin at 20–80 µg/ear/treatment inhibited ear edema and prostaglandin E₂ production in a mouse chronic skin inflammation model.
At total doses of 1,000 µg/site on dorsal skin, ginkgetin inhibited prostaglandin E₂ production by 65.6%; ginkgetin and the biflavonoid mixture (100–1,000 µg/ear) dose-dependently inhibited skin inflammation of croton oil-induced ear edema in mice.

8. Pharmacokinetics and Bioavailability

Ginkgetin exhibits relatively low oral bioavailability due to its biflavonoid structure and high lipophilicity, which result in poor aqueous solubility and limited intestinal absorption. Following absorption, ginkgetin is susceptible to extensive first-pass metabolism, further reducing systemic exposure. Detailed information regarding its metabolic pathways, active metabolites, and clearance mechanisms remains scarce.

The tissue distribution profile of ginkgetin has not been comprehensively characterized, making it difficult to accurately predict target organ exposure and therapeutic windows across different disease systems.

The unique C-C linked dimeric architecture confers distinct molecular planarity and lipophilicity, contributing to its enhanced membrane permeability — a property that may be relevant for blood-brain barrier penetration, though this has not been definitively confirmed in human pharmacokinetic studies. Most in vitro neuroprotection studies have employed concentrations that may not reflect achievable brain tissue levels.

The lack of standardized dosing regimens across existing preclinical studies complicates cross-study comparisons and extrapolation to humans. Although most studies report no obvious toxicity at pharmacologically effective doses, systematic toxicological evaluations — including long-term administration, reproductive toxicity, and organ-specific safety — are still lacking.

9. Safety Considerations and Interactions

9.1 Toxicology of Isolated Ginkgetin

Systematic toxicological data for isolated ginkgetin are limited. No human toxicity data exists for isolated ginkgetin. In vitro data suggests a wide therapeutic window. In vitro and animal studies show low cytotoxicity at bioactive concentrations. However, comprehensive GLP-compliant toxicology studies required for drug development have not been performed and published for ginkgetin as an isolated entity.

9.2 Antiplatelet Activity and Bleeding Risk

A pharmacologically relevant safety consideration is ginkgetin's demonstrated antiplatelet activity in human-derived platelet preparations. At low concentrations (0.5–1 µM), ginkgetin exhibited robust inhibition of collagen and arachidonic acid-induced platelet aggregation. This mechanism, shared with the broader class of Ginkgo biloba constituents, raises a theoretical concern about additive anticoagulant effects when combined with antiplatelet drugs (e.g., aspirin, clopidogrel) or anticoagulants (e.g., warfarin). This concern is extrapolated from the known class-level interactions of ginkgo preparations; specific interaction studies for isolated ginkgetin have not been published.

9.3 Pharmacokinetic Challenges and Formulation Issues

Poor oral bioavailability is predicted due to high molecular weight and lipophilicity, which are common to many biflavones. Advanced delivery systems would be required for therapeutic use. Ginkgetin is expected to undergo extensive Phase II metabolism (glucuronidation, sulfation), and its pharmacokinetics in humans are not well characterized.

9.4 Absence of Human Clinical Safety Data

The promising profile of ginkgetin is predominantly derived from preclinical studies, and clinical evidence in humans remains to be established. Clinical translation should ideally be initiated with a Phase 0 microdosing study to confirm human pharmacokinetics, followed by a Phase I trial to establish safety and a recommended Phase II dose. No such trials have been published as of the available literature.

9.5 Context Within Ginkgo biloba Extract (GBE) Safety

While isolated ginkgetin lacks a dedicated human safety record, its parent plant's extracts have a more extensively characterized safety profile. In a National Toxicology Program (NTP) 2-year rodent bioassay with GBE, hepatotoxicity was observed in rodents at doses ≥100 mg/kg in rats and ≥200 mg/kg in mice. These findings relate to whole extract and cannot be directly attributed to ginkgetin specifically; ginkgolides are specific compounds in G. biloba that have been known for neuroprotective, antioxidative, anti-inflammatory, anti-ischemic, and cardiovascular protective activities. The toxicological relevance of each fraction within the whole extract remains an active area of research.

9.6 Current Development Status

Addressing the current limitations through rigorous mechanistic, pharmacokinetic, and clinical studies will be critical for advancing ginkgetin from bench to bedside. For more than 30 years, ginkgetin has been the focus of scientific attention as a possible effective anticancer agent and as an agent with beneficial effects on neurological diseases. Despite this sustained interest, it remains a research-stage compound without approved therapeutic or dietary supplement applications.

References

Health Conditions

Health conditions that Ginkgetin may help support.

No conditions available.

Body Systems

Body systems that Ginkgetin may help support.

No body systems available.